Revolution Medicines (RVMD) Leases (2020 - 2026)

Revolution Medicines has reported Leases for 7 years, with the latest figure at $129.9 million in Q1 2026.

• For the quarter ending Q1 2026, Leases rose 12.19% year-over-year to $129.9 million; the trailing twelve-month figure through Mar 2026 stood at $129.9 million (up 12.19% YoY), and the FY2025 full-year result was $132.1 million, up 12.38% from the prior year.
• Leases for Q1 2026 stood at $129.9 million, down from $132.1 million in the prior quarter.
• The five-year high for Leases was $134.4 million in Q3 2025, with the low at $25.0 million in Q1 2023.
• Average Leases over 5 years is $82.7 million, with a median of $75.3 million recorded in 2024.
• Year-over-year, Leases plunged 57.32% in 2023 and surged 204.77% in 2024.
• Tracing RVMD's Leases over 5 years: stood at $55.1 million in 2022, then surged by 40.07% to $77.1 million in 2023, then jumped by 52.35% to $117.5 million in 2024, then increased by 12.38% to $132.1 million in 2025, then decreased by 1.66% to $129.9 million in 2026.
• The last three Leases figures came in at $129.9 million (Q1 2026), $132.1 million (Q4 2025), and $134.4 million (Q3 2025), per Business Quant data.

Peer Comparison